Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and...
Main Authors: | Rickinder Sethi, Nieves Gómez-Coronado, Adam J. Walker, Oliver D’Arcy Robertson, Bruno Agustini, Michael Berk, Seetal Dodd |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-09-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00605/full |
Similar Items
-
Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0
by: Estela Salagre, et al.
Published: (2018-11-01) -
The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment
by: Anna Giménez-Palomo, et al.
Published: (2021-07-01) -
Online ethics: where will the interface of mental health and the internet lead us?
by: Victoria Cosgrove, et al.
Published: (2017-08-01) -
Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
by: Clara Westwell-Roper, et al.
Published: (2020-04-01) -
Editorial: Placebo and Nocebo Effects in Psychiatry and Beyond
by: Katja Weimer, et al.
Published: (2020-08-01)